Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep.
Int J Parasitol
; 29(4): 531-4, 1999 Apr.
Article
en En
| MEDLINE
| ID: mdl-10428628
Experimental vaccine trials against hydatid disease have been undertaken in sheep using the EG95 recombinant vaccine. Challenge infection was with viable Echinococcus granulosus eggs obtained from a New Zealand isolate (dog/sheep cycle), an Australian isolate (dingo/wallaby cycle) and an Argentine isolate (dog/sheep cycle). Vaccination with EG95 conferred a high degree of protection against challenge with all three parasite isolates (protection range 96-100%). Taken together, the trials demonstrated that 86% of vaccinated sheep were completely free of viable hydatid cysts when examined approximately 1 year after challenge infection. Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades de las Ovejas
/
Vacunas Sintéticas
/
Equinococosis
/
Antígenos Helmínticos
Tipo de estudio:
Observational_studies
Límite:
Animals
País/Región como asunto:
America do sul
/
Argentina
/
Oceania
Idioma:
En
Revista:
Int J Parasitol
Año:
1999
Tipo del documento:
Article
Pais de publicación:
Reino Unido